UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Aug

    16

    How Winners of the UCB Family Epilepsy Scholarship Prepare to Go Back to School

    As students and parents prepare for a new school year, there can be a lot of stress  – from meeting new teachers and preparing for classes, to financial assistance and making new friends. For people living with epilepsy and their caregivers, the stress and worry surrounding back-to-school preparation is compounded.

    Jun

    13

    UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

    Jun

    06

    UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

    Today, UCB was pleased to host Her Royal Highness Princess Astrid of Belgium (HRH), Belgian dignitaries, and Belgian business leaders to visit our U.S. headquarters in Atlanta, Georgia.

    Jun

    01

    Life with MG & What I Wish For Everyone Who is Diagnosed

    May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis